サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1784139

低分子イノベーターCDMOの世界市場

Small Molecule Innovator CDMO

出版日
ページ情報
英文 273 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.46円
低分子イノベーターCDMOの世界市場
出版日: 2025年08月05日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 273 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

低分子イノベーターCDMOの世界市場は2030年までに789億米ドルに達する見込み

2024年に557億米ドルと推定される低分子イノベーターCDMOの世界市場は、分析期間2024-2030年にCAGR 6.0%で成長し、2030年には789億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである低分子原薬は、CAGR 6.9%を記録し、分析期間終了時には537億米ドルに達すると予測されます。低分子医薬品セグメントの成長率は、分析期間中CAGR 4.1%と推定されます。

米国市場は147億米ドルと推定、中国はCAGR 5.8％で成長予測

米国の低分子イノベーターCDMO市場は2024年に147億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに127億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは5.8%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ5.7%と5.0%と予測されています。欧州では、ドイツがCAGR 4.7%で成長すると予測されています。

世界の低分子イノベーターCDMO市場- 主要動向と促進要因のまとめ

低分子イノベーターCDMOはなぜ製薬業界に不可欠なのか？新薬開発におけるCDMOの役割を理解する

製薬業界はイノベーションと新薬開発を推進しており、複雑な低分子の初期段階の開発、最適化、製造に特化した低分子イノベーターCDMOの重要性が高まっています。大規模生産に重点を置く従来のCDMOとは異なり、イノベーターCDMOは、創薬、製剤開発、臨床試験の複雑な段階を乗り切る製薬企業をサポートします。バイオテクノロジー新興企業や中堅製薬企業が、有機合成、薬事戦略、複雑な化学プロセスに精通した専門CDMOに研究開発集約的なプロセスをアウトソーシングするケースが増えているため、この分野の市場は牽引力を増しています。低分子をベースとするがん治療薬、中枢神経系（CNS）治療薬、新規抗ウイルス治療薬に対する高い需要は、医薬品開発のタイムラインを短縮できる俊敏で高度な技術を持つイノベーターCDMOの必要性をさらに高めています。

最先端技術は低分子イノベーターCDMOをどのように変革しているか？医薬品合成と製造効率の進歩を探る

AIを活用した創薬、ハイスループットスクリーニング、連続製造における最近の進歩は、イノベーターCDMOの運営方法に革命をもたらしました。AIを活用した予測モデリングにより、リード化合物の迅速な同定が可能になり、前臨床研究や初期段階の開発に要する時間が短縮されました。連続フローケミストリーは反応効率を向上させ、プロセスの再現性を高めながら無駄を最小限に抑えています。さらに、マイクロ流体ベースの合成と無溶媒反応における革新は、グリーンケミストリーソリューションを可能にし、持続可能な医薬品製造の目標に合致しています。自動化とデジタルツインテクノロジーの採用が進むことで、より精密なプロセス制御が可能になり、新薬候補のスケーラビリティが向上しています。医薬品の研究開発がデータ主導で技術的に高度になるにつれ、革新的なCDMOは医薬品開発の効率と精度を高めるためにこれらの最先端ツールを統合しています。

低分子イノベーターCDMOの成長を阻む課題とは？規制上のハードル、コスト圧力、市場競争への対応

医薬品イノベーションにおいて重要な役割を担っているにもかかわらず、低分子イノベーターCDMOは規制上のハードル、高い開発コスト、市場競争といった課題に直面しています。低分子の新薬に対する規制当局の承認プロセスは長く複雑な場合があり、CDMOは進化する安全性と有効性のガイドラインに厳格に準拠し続ける必要があります。さらに、初期段階の医薬品開発には高いコストがかかるため、特に予算が限られている新興バイオテクノロジー企業にとっては財務上のリスクとなります。市場競争はもう一つの課題であり、多数のCDMOが契約を求めて競争しているため、専門的な専門知識、強力な実績、革新的なサービスの提供による差別化が必要となっています。こうした課題に対処するには、長期的な成長を維持するために、コンプライアンスフレームワークへの投資拡大、費用対効果の高いプロセス最適化戦略、顧客とのパートナーシップ強化が必要となります。

低分子イノベーターCDMO市場の成長を促すものは何か？主な拡大要因と業界発展の特定

低分子イノベーターCDMO市場の成長は、医薬品研究開発への投資の増加、迅速な創薬ソリューションへの需要の増加、合成化学の進歩など、いくつかの要因によって牽引されています。がん、神経疾患、感染症に対する低分子医薬品のパイプラインの拡大は、複雑な分子合成を専門とするイノベーターCDMOにビジネスチャンスをもたらしています。研究開発・製造のすべてを外注に依存するバーチャル製薬会社の動向は、専門的なCDMOパートナーシップの需要をさらに高めています。さらに、バイオテクノロジー新興企業への資金提供の増加や、医薬品イノベーションイニシアチブに対する政府の支援により、より広範な医薬品エコシステムにおけるイノベーターCDMOの役割が強化されています。個別化医療と特殊治療が進化し続ける中、低分子イノベーターCDMOの需要は増加し、医薬のブレークスルーを可能にする重要な存在として位置づけられると予想されます。

セグメント

製品タイプ（低分子API、低分子医薬品）、ステージタイプ（前臨床、臨床、商業）、顧客タイプ（製薬、バイオテクノロジー）、治療領域（循環器疾患、腫瘍、呼吸器疾患、神経、代謝疾患、感染症、その他）

調査対象企業の例

  • Aenova Group
  • AGC Biologics
  • Alcami Corporation
  • Apeloa Pharmaceutical
  • Aurigene Pharmaceutical Services
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International
  • CoreRx, Inc.
  • Delpharm
  • Emergent BioSolutions
  • Eurofins Scientific
  • Fujifilm Diosynth Biotechnologies
  • Hovione
  • Labcorp Drug Development
  • Lonza Group
  • MilliporeSigma
  • Patheon（Thermo Fisher Scientific）
  • PCI Pharma Services
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Veranova
  • Wheeler Bio
  • WuXi AppTec
  • Zhejiang Huahai Pharmaceutical

AIインテグレーション

当社は、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32964

Global Small Molecule Innovator CDMO Market to Reach US$78.9 Billion by 2030

The global market for Small Molecule Innovator CDMO estimated at US$55.7 Billion in the year 2024, is expected to reach US$78.9 Billion by 2030, growing at a CAGR of 6.0% over the analysis period 2024-2030. Small Molecule API, one of the segments analyzed in the report, is expected to record a 6.9% CAGR and reach US$53.7 Billion by the end of the analysis period. Growth in the Small Molecule Drug Product segment is estimated at 4.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$14.7 Billion While China is Forecast to Grow at 5.8% CAGR

The Small Molecule Innovator CDMO market in the U.S. is estimated at US$14.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$12.7 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.7% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.

Global Small Molecule Innovator CDMO Market - Key Trends & Drivers Summarized

Why Are Small Molecule Innovator CDMOs Crucial to the Pharmaceutical Industry? Understanding Their Role in New Drug Development

The pharmaceutical industry’s push toward innovation and novel drug discovery has elevated the importance of small molecule innovator CDMOs, which specialize in the early-stage development, optimization, and manufacturing of complex small molecules. Unlike traditional CDMOs, which focus on large-scale production, innovator CDMOs support pharmaceutical companies in navigating the intricate stages of drug discovery, formulation development, and clinical trials. This segment of the market has gained traction as biotech startups and mid-sized pharmaceutical firms increasingly outsource R&D-intensive processes to specialized CDMOs with deep expertise in organic synthesis, regulatory strategy, and complex chemical processes. The high demand for small molecule-based oncology drugs, central nervous system (CNS) treatments, and novel antiviral therapies has further strengthened the need for agile and highly skilled innovator CDMOs capable of expediting drug development timelines.

How Are Cutting-Edge Technologies Transforming Small Molecule Innovator CDMOs? Exploring Advancements in Drug Synthesis and Manufacturing Efficiency

Recent advancements in AI-driven drug discovery, high-throughput screening, and continuous manufacturing have revolutionized the way innovator CDMOs operate. AI-powered predictive modeling enables faster identification of lead compounds, reducing the time required for preclinical research and early-stage development. Continuous flow chemistry has improved reaction efficiency, minimizing waste while enhancing process reproducibility. Additionally, innovations in microfluidic-based synthesis and solvent-free reactions have enabled green chemistry solutions, aligning with sustainable pharmaceutical manufacturing goals. The increasing adoption of automation and digital twin technology has allowed for more precise process control, improving scalability for emerging drug candidates. As pharmaceutical R&D becomes more data-driven and technologically advanced, innovator CDMOs are integrating these cutting-edge tools to enhance drug development efficiency and precision.

What Challenges Are Limiting the Growth of Small Molecule Innovator CDMOs? Addressing Regulatory Hurdles, Cost Pressures, and Market Competition

Despite their critical role in pharmaceutical innovation, small molecule innovator CDMOs face challenges such as regulatory hurdles, high development costs, and market competition. Regulatory approval processes for new small-molecule drugs can be lengthy and complex, requiring CDMOs to maintain stringent compliance with evolving safety and efficacy guidelines. Additionally, the high cost of early-stage drug development poses financial risks, particularly for emerging biotech firms with limited budgets. Market competition is another challenge, as numerous CDMOs compete for contracts, necessitating differentiation through specialized expertise, strong track records, and innovative service offerings. Addressing these challenges requires increased investment in compliance frameworks, cost-effective process optimization strategies, and enhanced client partnerships to sustain long-term growth.

What’s Driving the Growth of the Small Molecule Innovator CDMO Market? Identifying Key Expansion Factors and Industry Developments

The growth in the small molecule innovator CDMO market is driven by several factors, including rising investments in pharmaceutical R&D, increasing demand for rapid drug discovery solutions, and advancements in synthetic chemistry. The expanding pipeline of small-molecule drugs for cancer, neurological disorders, and infectious diseases has created opportunities for innovator CDMOs specializing in complex molecular synthesis. The growing trend of virtual pharmaceutical companies, which rely entirely on outsourced R&D and manufacturing, has further fueled demand for specialized CDMO partnerships. Additionally, increased funding for biotech startups and government support for drug innovation initiatives have strengthened the role of innovator CDMOs in the broader pharmaceutical ecosystem. As personalized medicine and specialty therapeutics continue to evolve, the demand for small molecule innovator CDMOs is expected to rise, positioning them as key enablers of pharmaceutical breakthroughs.

SCOPE OF STUDY:

The report analyzes the Small Molecule Innovator CDMO market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product (Small Molecule API, Small Molecule Drug Product); Stage Type (Preclinical, Clinical, Commercial); Customer Type (Pharmaceutical, Biotechnology); Therapeutic Area (Cardiovascular disease, Oncology, Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 36 Featured) -

  • Aenova Group
  • AGC Biologics
  • Alcami Corporation
  • Apeloa Pharmaceutical
  • Aurigene Pharmaceutical Services
  • Boehringer Ingelheim
  • Cambrex Corporation
  • Catalent, Inc.
  • CordenPharma International
  • CoreRx, Inc.
  • Delpharm
  • Emergent BioSolutions
  • Eurofins Scientific
  • Fujifilm Diosynth Biotechnologies
  • Hovione
  • Labcorp Drug Development
  • Lonza Group
  • MilliporeSigma
  • Patheon (Thermo Fisher Scientific)
  • PCI Pharma Services
  • Piramal Pharma Solutions
  • Recipharm AB
  • Samsung Biologics
  • Siegfried Holding AG
  • Teva Pharmaceutical Industries
  • Thermo Fisher Scientific
  • Veranova
  • Wheeler Bio
  • WuXi AppTec
  • Zhejiang Huahai Pharmaceutical

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Small Molecule Innovator CDMO - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in Early-Stage Biotech Pipelines Throws the Spotlight on Small Molecule Innovator CDMO Partnerships
    • Growing Complexity in Molecular Structures Drives Demand for Specialized Synthetic Route Development
    • Expansion of Accelerated Approval Programs Spurs Early Engagement With Innovator-Focused CDMOs
    • OEM Focus on Integrated Drug Substance and Drug Product Services Strengthens End-to-End Innovation Support
    • Rising Demand for High-Potency APIs and Oncology Compounds Expands Scope of Niche CDMO Expertise
    • OEM Development of Agile, Small-Batch Manufacturing Models Enhances Speed to IND and First-in-Human Trials
    • Growth in Virtual Biotech Companies Strengthens Demand for Flexible and Collaborative CDMO Models
    • OEM Strategies for Early Process Chemistry and Analytical Method Development Improve Tech Transfer Success
    • Expansion of Orphan and Rare Disease Programs Spurs Need for Clinical-Scale Customization and Agility
    • OEM Emphasis on IP Protection, Project Confidentiality, and Regulatory Support Enhances Innovator Trust
    • Surging Need for Rapid Formulation Prototyping and Preclinical Supplies Drives Demand for Agile CDMO Capacity
    • OEM Investments in Flow Chemistry, Enabling Technologies, and Green Synthesis Bolster Innovation Pipeline
    • Growth in Complex Solubility and Bioavailability Challenges Spurs Early Engagement in Formulation Science
    • OEM Collaboration With AI-Based Drug Discovery Platforms Strengthens Competitive Positioning in Early R&D
    • Increasing Need for Integrated CMC Services Under Single Umbrella Streamlines Development Timelines
    • OEM Expansion Into Preformulation, Toxicology Batch Production, and Early Stability Testing Enhances Value Proposition
    • Rising Focus on NCE-Specific Customization Supports Differentiation in the CDMO Selection Process
    • OEM Emphasis on Analytical Method Validation and IND-Enabling Data Packages Drives Regulatory Readiness
    • Growth in Partnering Models With Shared Milestones and Risk-Sharing Structures Promotes Strategic Alignment
    • Focus on Rapid Response CDMO Models for Emerging Therapeutic Areas Accelerates First-Mover Advantage
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Small Molecule Innovator CDMO Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Small Molecule Innovator CDMO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Small Molecule Innovator CDMO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Small Molecule API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Small Molecule API by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Small Molecule API by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Small Molecule Drug Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Small Molecule Drug Product by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Small Molecule Drug Product by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Respiratory disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Respiratory disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Respiratory disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Neurology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Neurology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Metabolic Disorders by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Metabolic Disorders by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Infectious Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Infectious Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Others by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Others by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Cardiovascular disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Cardiovascular disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Cardiovascular disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Preclinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Preclinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Preclinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Clinical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Clinical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Commercial by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Commercial by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Pharmaceutical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Pharmaceutical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Biotechnology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Biotechnology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: USA 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Canada 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 68: Canada Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Canada Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Canada 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • JAPAN
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Japan 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 77: Japan Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Japan Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Japan 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 80: Japan Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Japan Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Japan 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • CHINA
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 83: China Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: China Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: China 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 86: China Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: China Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: China 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 89: China Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: China Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: China 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 92: China Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: China Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: China 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • EUROPE
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 95: Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for Small Molecule Innovator CDMO by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Europe 15-Year Perspective for Small Molecule Innovator CDMO by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 98: Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Europe Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Europe 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 101: Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Europe Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Europe 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 104: Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Europe Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Europe 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 107: Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Europe Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Europe 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • FRANCE
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 110: France Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: France Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: France 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 113: France Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: France Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: France 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 116: France Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: France Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: France 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 119: France Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: France Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: France 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • GERMANY
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 122: Germany Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Germany Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Germany 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 125: Germany Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Germany Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Germany 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 128: Germany Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Germany Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Germany 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 131: Germany Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Germany Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Germany 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 134: Italy Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Italy Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Italy 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 137: Italy Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Italy Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Italy 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 140: Italy Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Italy Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Italy 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 143: Italy Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Italy Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Italy 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 146: UK Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: UK Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: UK 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 149: UK Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: UK Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: UK 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 152: UK Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: UK Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: UK 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 155: UK Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: UK Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: UK 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 158: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Europe Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Europe 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 161: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Europe Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Rest of Europe 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 164: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Europe Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Europe 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Europe Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Europe Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Europe 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Small Molecule Innovator CDMO Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 170: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Asia-Pacific Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Asia-Pacific 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 173: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Asia-Pacific Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Asia-Pacific 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 176: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Asia-Pacific Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Asia-Pacific 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 179: Asia-Pacific Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Asia-Pacific Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Asia-Pacific 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 182: Rest of World Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Rest of World Historic Review for Small Molecule Innovator CDMO by Product - Small Molecule API and Small Molecule Drug Product Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Rest of World 15-Year Perspective for Small Molecule Innovator CDMO by Product - Percentage Breakdown of Value Sales for Small Molecule API and Small Molecule Drug Product for the Years 2015, 2025 & 2030
    • TABLE 185: Rest of World Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Rest of World Historic Review for Small Molecule Innovator CDMO by Therapeutic Area - Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Rest of World 15-Year Perspective for Small Molecule Innovator CDMO by Therapeutic Area - Percentage Breakdown of Value Sales for Respiratory disorders, Neurology, Metabolic Disorders, Infectious Diseases, Others, Cardiovascular disease and Oncology for the Years 2015, 2025 & 2030
    • TABLE 188: Rest of World Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of World Historic Review for Small Molecule Innovator CDMO by Stage Type - Preclinical, Clinical and Commercial Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of World 15-Year Perspective for Small Molecule Innovator CDMO by Stage Type - Percentage Breakdown of Value Sales for Preclinical, Clinical and Commercial for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of World Recent Past, Current & Future Analysis for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of World Historic Review for Small Molecule Innovator CDMO by Customer Type - Pharmaceutical and Biotechnology Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of World 15-Year Perspective for Small Molecule Innovator CDMO by Customer Type - Percentage Breakdown of Value Sales for Pharmaceutical and Biotechnology for the Years 2015, 2025 & 2030

IV. COMPETITION